| |
|
| Interactions
with Alpha-Linolenic Acid (ALA) | |
| HMG-CoA
Reductase Inhibitors
The addition of alpha-linolenic acid (40 µmol/L) to cultured human liver
cells pretreated with lovastatin (10 µmol/L) prevented the increase in
arachidonic acid-rich lipids that was associated with the drug (Hrboticky et al.
1996). More studies with ALA-supplemented diets are warranted to confirm these
preliminary, in vitro findings. The combination of ALA and HMG-CoA reductase
inhibitors may offer a cardioprotective benefit for patients on this
therapy. |
|
|
| References |
|
|
Hrboticky N, Zimmer B, Weber PC. Alpha-Linolenic acid reduces the
lovastatin-induced rise in arachidonic acid and elevates cellular and
lipoprotein eicosapentaenoic and docosahexaenoic acid levels in Hep G2 cells.
J Nutr Biochem. 1996;7:465-471. |
|
|
Copyright © 2000 Integrative Medicine
Communications This publication contains
information relating to general principles
of medical care that should not in any event be construed as specific
instructions for individual patients. The publisher does not accept any
responsibility for the accuracy of the information or the consequences arising
from the application, use, or misuse of any of the information contained herein,
including any injury and/or damage to any person or property as a matter of
product liability, negligence, or otherwise. No warranty, expressed or implied,
is made in regard to the contents of this material. No claims or endorsements
are made for any drugs or compounds currently marketed or in investigative use.
The reader is advised to check product information (including package inserts)
for changes and new information regarding dosage, precautions, warnings,
interactions, and contraindications before administering any drug, herb, or
supplement discussed herein. | |
